© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 13, 981-989,
July 2, 2003
© 2003 Oxford University Press
ARTICLE |
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Affiliation of authors: Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California, San Francisco (UCSF)/Mt. Zion Comprehensive Cancer Center, UCSF, San Francisco.
Correspondence to: Peter R. Carroll, M.D., UCSF/Mt. Zion Cancer Center, 1600 Divisadero St., 3rd Floor, San Francisco, CA 941150-1711 (e-mail: pcarroll{at}urol.ucsf.edu).
Background: Recent reports have suggested that growing numbers of patients with localized prostate cancer are receiving androgen deprivation therapy as primary or neoadjuvant treatment, yet sparse clinical evidence supports the use of such treatment except among patients with high-risk or locally advanced disease receiving external beam radiotherapy. We describe national trends in the use of androgen deprivation therapy for localized disease. Methods: CaPSURE is an observational database of 7195 patients with prostate cancer. This study included 3439 of these patients who were diagnosed since 1989, had clinical staging information available, and were treated with radical prostatectomy, radiation therapy, or primary androgen deprivation therapy (PADT). High-, intermediate-, and low-risk groups were defined by serum prostate-specific antigen level, Gleason score, and clinical tumor stage. Time trends in the use of PADT and neoadjuvant androgen deprivation therapy (NADT) were analyzed. All statistical tests were two-sided. Results: Rates of PADT use rose sharply between 1989 and 2001, from 4.6% (95% confidence interval [CI] = 3.4% to 5.8%) to 14.2% (95% CI = 12.2% to 16.2%), from 8.9% (95% CI = 7.3% to 10.5%) to 19.7% (95% CI = 17.5% to 21.9%), and from 32.8% (95% CI = 29.9% to 35.7%) to 48.2% (95% CI = 45.1% to 51.3%) (all P<.001) in low-, intermediate-, and high-risk groups, respectively. NADT use also increased in association with radical prostatectomy (2.9% [95% CI = 2.1% to 3.7%] to 7.8% [95% CI = 6.5% to 9.1%] of patients, P = .003) and external beam radiotherapy (9.8% [95% CI = 7.5% to 12.1%] to 74.6% [95% CI = 70.8% to 78.4%], P<.001) across all risk levels combined. Rates of NADT use among patients treated with brachytherapy also increased but not statistically significantly (7.4% [95% CI = 3.5% to 11.3%] to 24.6% [95% CI = 18.2% to 31.0%], P = .100). Conclusions: Rates of both PADT and NADT are increasing across risk groups and treatment types. Future clinical trials must define more clearly the appropriate role of hormonal therapy in localized prostate cancer, and their results should shape updated practice guidelines.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, M. J. Barry, A. Zietman, M. O'Leary, E. Walker-Corkery, et al. Outcomes of Localized Prostate Cancer Following Conservative Management JAMA, September 16, 2009; 302(11): 1202 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Cooperberg, S. Hinotsu, M. Namiki, K. Ito, J. Broering, P. R. Carroll, and H. Akaza Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy J. Clin. Oncol., September 10, 2009; 27(26): 4306 - 4313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Uhlman, J. W. Moul, P. Tang, D. A. Stackhouse, and L. Sun Review: Risk stratification in the hormonal treatment of patients with prostate cancer Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 79 - 94. [Abstract] [PDF]
|
|
|
|
|
|
S. M.H. Alibhai, M. Duong-Hua, R. Sutradhar, N. E. Fleshner, P. Warde, A. M. Cheung, and L. F. Paszat Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes J. Clin. Oncol., July 20, 2009; 27(21): 3452 - 3458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Albertsen Androgen Deprivation in Prostate Cancer -- Step by Step N. Engl. J. Med., June 11, 2009; 360(24): 2572 - 2574. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, P. Choyke, D. S. Coffey, and for The Prostate Cancer Imaging Working Group Challenges in Clinical Prostate Cancer: Role of Imaging Am. J. Roentgenol., June 1, 2009; 192(6): 1455 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Weinreb, J. D. Blume, F. V. Coakley, T. M. Wheeler, J. B. Cormack, C. K. Sotto, H. Cho, A. Kawashima, C. M. Tempany-Afdhal, K. J. Macura, et al. Prostate Cancer: Sextant Localization at MR Imaging and MR Spectroscopic Imaging before Prostatectomy--Results of ACRIN Prospective Multi-institutional Clinicopathologic Study Radiology, April 1, 2009; 251(1): 122 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wang, T. Yuasa, N. Tsuchiya, S. Maita, T. Kumazawa, T. Inoue, M. Saito, Z. Ma, T. Obara, H. Tsuruta, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy Endocr. Relat. Cancer, December 1, 2008; 15(4): 943 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Greenspan, J. B. Nelson, D. L. Trump, J. M. Wagner, M. E. Miller, S. Perera, and N. M. Resnick Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy J. Clin. Oncol., September 20, 2008; 26(27): 4426 - 4434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, and S.-L. Yao Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer JAMA, July 9, 2008; 300(2): 173 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Engstrom Hot Flashes in Prostate Cancer: State of the Science American Journal of Men's Health, June 1, 2008; 2(2): 122 - 132. [Abstract] [PDF]
|
|
|
|
 |
|
 H. D. Lewis, A. Winter, T. F. Murphy, S. Tripathi, V. N. Pandey, and B. E. Barton STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends Mol. Cancer Ther., June 1, 2008; 7(6): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. B. Shahinian, Y.-f. Kuo, J. L. Freeman, E. Orihuela, and J. S. Goodwin Characteristics of Urologists Predict the Use of Androgen Deprivation Therapy for Prostate Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5359 - 5365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hinotsu, H. Akaza, M. Usami, O. Ogawa, S. Kagawa, T. Kitamura, T. Tsukamoto, S. Naito, M. Namiki, Y. Hirao, et al. Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaP Jpn. J. Clin. Oncol., October 26, 2007; (2007) hym098v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Greenspan, J. B. Nelson, D. L. Trump, and N. M. Resnick Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial Ann Intern Med, March 20, 2007; 146(6): 416 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Keating, A. J. O'Malley, and M. R. Smith Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer J. Clin. Oncol., September 20, 2006; 24(27): 4448 - 4456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst, June 21, 2006; 98(12): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med, February 27, 2006; 166(4): 465 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q. Purnell, L. B. Bland, M. Garzotto, D. Lemmon, E. M. Wersinger, C. W. Ryan, J. D. Brunzell, and T. M. Beer Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer J. Lipid Res., February 1, 2006; 47(2): 349 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Cooperberg, J. W. Moul, and P. R. Carroll The Changing Face of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8146 - 8151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Pisansky External Beam Radiotherapy as Curative Treatment of Prostate Cancer Mayo Clin. Proc., July 1, 2005; 80(7): 883 - 898. [Abstract] [PDF]
|
|
|
|
|
|
V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin Risk of Fracture after Androgen Deprivation for Prostate Cancer N. Engl. J. Med., January 13, 2005; 352(2): 154 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Shaw, R. Etzioni, S. B. Zeliadt, A. Mariotto, K. Karnofski, D. F. Penson, N. S. Weiss, and E. J. Feuer An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States Am. J. Epidemiol., December 1, 2004; 160(11): 1059 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Potosky, W. W. Davis, R. M. Hoffman, J. L. Stanford, R. A. Stephenson, D. F. Penson, and L. C. Harlan Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study J Natl Cancer Inst, September 15, 2004; 96(18): 1358 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shukla and S. Gupta Suppression of Constitutive and Tumor Necrosis Factor {alpha}-Induced Nuclear Factor (NF)-{kappa}B Activation and Induction of Apoptosis by Apigenin in Human Prostate Carcinoma PC-3 Cells: Correlation with Down-Regulation of NF-{kappa}B-Responsive Genes Clin. Cancer Res., May 1, 2004; 10(9): 3169 - 3178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Sandler and M. L. DeSilvio Surrogate End Points for Prostate Cancer: What Is Prostate-Specific Antigen Telling Us? J Natl Cancer Inst, September 17, 2003; 95(18): 1352 - 1353. [Full Text] [PDF]
|
|
|
|
|
|
M.J. Quinn Cancer Trends in the United States--A View From Europe J Natl Cancer Inst, September 3, 2003; 95(17): 1258 - 1261. [Full Text] [PDF]
|
|
|
|
|
|
P. C. Albertsen The Prostate Cancer Conundrum J Natl Cancer Inst, July 2, 2003; 95(13): 930 - 931. [Full Text] [PDF]
|
|